DA Davidson analyst Linda Bolton Weiser raised her price target on Medifast to $249 and kept her Buy rating after its Q2 results showed accelerating sales growth. The analyst adds that operating profit rose 51%, while Sequential Health Coach growth accelerated to 18%. Weiser raises her Medifast EPS view to $4.50 from $3.65 and believes that view remains conservative as it assumes “very little” leverage and deceleration of sequential Health Coach growth going forward.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.